Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label FE 999326 intravesical treatment in Japanese patients with high-grade BCG-unresponsive NMIBC
jRCT2053220142Phase 3Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals Co., Ltd.
- Start
- Oct 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nadofaragene firadenovec in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by Ferring Pharmaceuticals Co., Ltd. Primary endpoint: Complete response at Month 12 in subjects with CIS. Started Oct 2022; status: active, not recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2053220142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053220142.